July 25, 2018

Eli Lilly CEO denounces plan to consider drug imports

From: The Hill

Executives at Eli Lilly, one of the nation’s largest pharmaceutical companies, are denouncing the Trump administration’s proposal to consider ways to import prescription drugs from other countries.


Azar has said he thinks rebates give an incentive for higher drug prices, since both the PBM and drug company get a cut. A proposal that would remove certain legal protections around rebates is currently under review by the White House Office of Management and Budget.

Read Complete Article

No Comments »

No comments yet.

Leave a Reply

Name not required for anonymous comments. Email is optional and will not be published.